Early Alzheimer's data sound good, but Biogen has much to prove
This article was originally published in Scrip
Executive Summary
Could Biogen Idec have a successful treatment for Alzheimer's disease in a class of drugs where others have failed before? Maybe, but the company will have a lot to prove as it "very aggressively" pursues Phase III development following what appear to be promising Phase Ib results for BIIB037.